NEW YORK, March 10, 2020 /PRNewswire/ -- Spherix
Incorporated (Nasdaq: SPEX) today provided an update on the
recently announced treatment for Coronavirus technology optioned by
the Company.
As noted in patent number 10,434,116 "Methods of Treating
Coronavirus Infection," the technology provides methods for
treating a coronavirus infection. The technology was
developed by researchers by first using computers to screen 290
drugs for antiviral activity against SARS-CoV and/or MERS-CoV.
Pharmacological classes of compounds were identified as showing
antiviral activity against either or both MERS-CoV and SARS-CoV,
with no or low toxicity. These pharmacological classes include
neurotransmitter inhibitors, kinase signaling inhibitors, estrogen
receptor inhibitors, DNA metabolism inhibitors, and anti-parasitic
agents.
The work showed that certain compounds, alone or in combination
with the antiviral drugs, can have a therapeutic effect against
SARS and MERS as measured by in vitro antiviral activity assays and
in in vivo rodent and non-human primate models of Coronavirus
infection.
This invention was made with government support under
Grant Number AI095569 awarded by the
National Institutes of Health. As a result, the NIH has certain
rights in the invention. Under the Option, Spherix has until
the end of May of 2020 to complete its due diligence and execute a
license agreement for commercial development.
About Spherix
Spherix Incorporated, a Delaware corporation (the "Company"), was
initially formed in 1967 and is currently a biotechnology company
with a diverse portfolio of small-molecule anti-cancer
therapeutics. The Company's platform consists of patented
technology from leading universities and researchers and we are
currently in the process of developing an innovative therapeutic
drug platform through strong partnerships with world renowned
educational institutions, including The University of Texas at Austin and Wake Forest University. Our diverse pipeline of
therapeutics includes therapies for pancreatic cancer, acute
myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). In
addition, we are constantly seeking to grow our pipe to treat unmet
medical needs in oncology
Forward-Looking Statements
Certain statements in this press release constitute
"forward-looking statements" within the meaning of the federal
securities laws. Words such as "may," "might," "will," "should,"
"believe," "expect," "anticipate," "estimate," "continue,"
"predict," "forecast," "project," "plan," "intend" or similar
expressions, or statements regarding intent, belief, or current
expectations, are forward-looking statements. While the Company
believes these forward-looking statements are reasonable, undue
reliance should not be placed on any such forward-looking
statements, which are based on information available to us on the
date of this release. These forward looking statements are based
upon current estimates and assumptions and are subject to various
risks and uncertainties, including without limitation those set
forth in the Company's filings with the SEC, not limited to Risk
Factors relating to its patent business contained therein. Thus,
actual results could be materially different. The Company expressly
disclaims any obligation to update or alter statements whether as a
result of new information, future events or otherwise, except as
required by law.
Contact:
Investor Relations: Hayden IR
Brett
Maas, Managing Partner
Phone: (646) 536-7331
Email: brett@haydenir.com
www.haydenir.com
Spherix: Phone: 212-745-1373
Email:
investorrelations@spherix.com
www.spherix.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/shareholder-update-on-treatment-for-coronavirus-optioned-by-spherix-301020939.html
SOURCE Spherix Incorporated